Seattle Genetics to Host Conference Call & Webcast Discussion of Fourth Quarter & Full Year 2019 Financial Results on Februar...

Date : 01/21/2020 @ 1:30PM
Source : Business Wire
Stock : Seattle Genetics Inc (SGEN)
Quote : 120.59  4.08 (3.50%) @ 7:58PM

Seattle Genetics to Host Conference Call & Webcast Discussion of Fourth Quarter & Full Year 2019 Financial Results on Februar...

Seattle Genetics (NASDAQ:SGEN)
Historical Stock Chart

3 Months : From Jan 2020 to Apr 2020

Click Here for more Seattle Genetics Charts.

Seattle Genetics, Inc. (Nasdaq: SGEN) announced today that it will report its fourth quarter and full year 2019 financial results on Thursday, February 6, 2020 after the close of financial markets. Following the announcement, company management will host a conference call and webcast discussion of the results and provide a general corporate update. Access to the event can be obtained as follows:

LIVE access on Thursday, February 6, 2020 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time

  • Telephone 800-353-6461 (domestic) or +1 334-323-0501 (international); conference ID 7290215
  • Webcast with slides available at www.seattlegenetics.com in the Investors section

REPLAY access

  • Telephone replay will be available beginning at approximately 4:30 p.m. PT on Thursday, February 6, 2020 through 5:00 p.m. PT on Sunday, February 9, 2020 by calling 888-203-1112 (domestic) or +1 719-457-0820 (international); conference ID 7290215
  • Webcast replay will be available on the Seattle Genetics website at www.seattlegenetics.com in the Investors section

About Seattle Genetics

Seattle Genetics, Inc. is a global biotechnology company that discovers, develops and commercializes transformative medicines targeting cancer to make a meaningful difference in people’s lives. ADCETRIS® (brentuximab vedotin) and PADCEVTM (enfortumab vedotin-ejfv) use the company’s industry-leading antibody-drug conjugate (ADC) technology designed to bring a powerful medicine directly to cancer cells. ADCETRIS is approved for the treatment of several types of CD30-expressing lymphomas, and PADCEV is approved to treat adults with metastatic urothelial cancer. In addition, investigational agent tucatinib, a small molecule tyrosine kinase inhibitor, is in late-stage development for HER2-positive metastatic breast cancer, and in clinical development for metastatic colorectal cancer. The company is headquartered in Bothell, Washington, and has offices in California, Switzerland and the European Union. For more information on our robust pipeline, visit www.seattlegenetics.com and follow @SeattleGenetics on Twitter.

Investors Peggy Pinkston (425) 527-4160 ppinkston@seagen.com

Media Monique Greer (425) 527-4641 mgreer@seagen.com

Latest SGEN Messages

{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}}

Loading Messages....


No posts yet, be the first! No {{symbol}} Message Board. Create One! See More Posts on {{symbol}} Message Board See More Message Board Posts


Your Recent History
LSE
GKP
Gulf Keyst..
LSE
QPP
Quindell
FTSE
UKX
FTSE 100
LSE
IOF
Iofina
FX
GBPUSD
UK Sterlin..
Stocks you've viewed will appear in this box, letting you easily return to quotes you've seen previously.

Register now to create your own custom streaming stock watchlist.


NYSE, AMEX, and ASX quotes are delayed by at least 20 minutes.
All other quotes are delayed by at least 15 minutes unless otherwise stated.